PMID- 35150441
OWN - NLM
STAT- MEDLINE
DCOM- 20220412
LR  - 20220412
IS  - 1096-9098 (Electronic)
IS  - 0022-4790 (Linking)
VI  - 125
IP  - 6
DP  - 2022 May
TI  - Clinicopathological and prognostic significance of HER2 status in surgically 
      resected colorectal liver metastases.
PG  - 991-1001
LID - 10.1002/jso.26815 [doi]
AB  - BACKGROUND: The clinicopathological and prognostic significance of human 
      epidermal growth factor receptor 2 (HER2) status in surgically resected 
      colorectal liver metastases (CRLM) remains uncertain. METHODS: HER2 expression 
      was evaluated by immunohistochemical (IHC) in two CRLM tissue microarrays (TMAs). 
      For samples with an IHC score of 2+ or 3+, fluorescence in situ hybridization 
      (FISH) was performed to assess HER2 amplification. The association of HER2 
      amplification with clinicopathological parameters and prognosis was assessed 
      using Fisher's exact test and Kaplan-Meier method, respectively. RESULTS: HER2 
      expression was consistent between primary tumor and liver metastases in 66.9% 
      (85/127) cases (r = 0.643, p = 0.001). After FISH validation, HER2 amplification 
      was identified in 6.25% (13/208) patients. HER2 amplification was significantly 
      associated with age (p = 0.017), bilobar involvement (p = 0.005) and left-sided 
      RAS/RAF wild-type status (p = 0.002). In the overall cohort, HER2 amplification 
      was correlated with significantly worse relapse-free survival (RFS). Further 
      stratification revealed that among left-sided RAS/RAF wild-type cases, HER2 
      amplification was significantly associated with worse overall survival (OS) (30.2 
      vs. 50.9 months, p = 0.040) and RFS (5.77 vs. 19.97 months, p = 0.017). 
      CONCLUSION: HER2 amplification is more enriched in CRLMs with younger age, 
      left-sided RAS/RAF wild-type, and bilobar involvement. Moreover, HER2 
      amplification predicts a poorer prognosis especially in left-sided RAS/RAF 
      wild-type CRLMs.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Han, Jiahao
AU  - Han J
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Wang, Xiangyu
AU  - Wang X
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Zhang, Chong
AU  - Zhang C
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Wu, Qian
AU  - Wu Q
AD  - Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Ma, Xiaochen
AU  - Ma X
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Li, Yitong
AU  - Li Y
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Chen, Zhenmei
AU  - Chen Z
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Zhang, Rui
AU  - Zhang R
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Zhang, Guo
AU  - Zhang G
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Lin, Jing
AU  - Lin J
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Lu, Lu
AU  - Lu L
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Zhu, Wenwei
AU  - Zhu W
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Jia, Huliang
AU  - Jia H
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Zhang, Jubo
AU  - Zhang J
AD  - Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, 
      China.
FAU - Fan, Jie
AU  - Fan J
AD  - Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Chen, Jinhong
AU  - Chen J
AD  - Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 
      China.
LA  - eng
GR  - 2017ZX10203207/National Natural Science and Technology Major Project of the 
      thirteenth Five Year Plan/
GR  - 81472677/National Natural Science Foundation of China/
GR  - 82070655/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20220212
PL  - United States
TA  - J Surg Oncol
JT  - Journal of surgical oncology
JID - 0222643
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Colorectal Neoplasms/genetics/surgery
MH  - Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Liver Neoplasms/genetics/secondary/surgery
MH  - Prognosis
MH  - Receptor, ErbB-2/metabolism
OTO - NOTNLM
OT  - HER2
OT  - colorectal cancer
OT  - liver metastases
OT  - prognosis
EDAT- 2022/02/13 06:00
MHDA- 2022/04/13 06:00
CRDT- 2022/02/12 12:08
PHST- 2022/01/11 00:00 [revised]
PHST- 2021/11/27 00:00 [received]
PHST- 2022/01/31 00:00 [accepted]
PHST- 2022/02/13 06:00 [pubmed]
PHST- 2022/04/13 06:00 [medline]
PHST- 2022/02/12 12:08 [entrez]
AID - 10.1002/jso.26815 [doi]
PST - ppublish
SO  - J Surg Oncol. 2022 May;125(6):991-1001. doi: 10.1002/jso.26815. Epub 2022 Feb 12.